Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Union Hospital of Cecil County
mi
from
Elkton MD, MD
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Union Hospital of Cecil County
mi
from
Elkton MD, MD
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Washington University School of Medicine
mi
from
Saint Louis, MO
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Good Samaritan Hospital - Dayton
mi
from
Dayton, OH
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Good Samaritan Hospital - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Dayton CCOP
mi
from
Dayton, OH
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Dayton CCOP
mi
from
Dayton, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Miami Valley Hospital
mi
from
Dayton, OH
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Samaritan North Health Center
mi
from
Dayton, OH
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Samaritan North Health Center
mi
from
Dayton, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Grandview Hospital
mi
from
Dayton, OH
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Grandview Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Blanchard Valley Hospital
mi
from
Findlay, OH
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Blanchard Valley Hospital
mi
from
Findlay, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Atrium Medical Center - Middletown Regional Hospital
mi
from
Franklin, OH
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Atrium Medical Center - Middletown Regional Hospital
mi
from
Franklin, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Wayne Hospital
mi
from
Greenville, OH
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Wayne Hospital
mi
from
Greenville, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Kettering Medical Center
mi
from
Kettering, OH
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Kettering Medical Center
mi
from
Kettering, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Upper Valley Medical Center
mi
from
Troy, OH
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Upper Valley Medical Center
mi
from
Troy, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Greene Memorial Hospital
mi
from
Xenia, OH
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Greene Memorial Hospital
mi
from
Xenia, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Oncare Hawaii Inc-Pali Momi
mi
from
Aiea, HI
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Oncare Hawaii Inc-Pali Momi
mi
from
Aiea, HI
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Pali Momi Medical Center
mi
from
Aiea, HI
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Pali Momi Medical Center
mi
from
Aiea, HI
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Oncare Hawaii Inc-POB II
mi
from
Honolulu, HI
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Oncare Hawaii Inc-POB II
mi
from
Honolulu, HI
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Saint Joseph Medical Center
mi
from
Bloomington, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Saint Joseph Medical Center
mi
from
Bloomington, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Northwestern University
mi
from
Chicago, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare - Galesburg
mi
from
Galesburg, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare - Galesburg
mi
from
Galesburg, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Community Cancer Center Foundation
mi
from
Normal, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Community Cancer Center Foundation
mi
from
Normal, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Ottawa Regional Hospital and Healthcare Center
mi
from
Ottawa, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Ottawa Regional Hospital and Healthcare Center
mi
from
Ottawa, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois Oncology Research Association CCOP
mi
from
Peoria, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois Oncology Research Association CCOP
mi
from
Peoria, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois Valley Hospital
mi
from
Peru, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois Valley Hospital
mi
from
Peru, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Carle Cancer Center
mi
from
Urbana, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Franciscan Saint Francis Health-Indianapolis
mi
from
Indianapolis, IN
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Franciscan Saint Francis Health-Indianapolis
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Siouxland Regional Cancer Center
mi
from
Sioux City, IA
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Siouxland Regional Cancer Center
mi
from
Sioux City, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Saint Luke's Regional Medical Center
mi
from
Sioux City, IA
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Saint Luke's Regional Medical Center
mi
from
Sioux City, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
The Mayo Clinic
mi
from
Rochester, MN
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer
Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer
Status: Enrolling
Updated:  9/28/2015
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer
Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer
Status: Enrolling
Updated: 9/28/2015
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
NIR Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo
NIR (Near Infrared Spectral Tomography)Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo.
Status: Enrolling
Updated:  9/28/2015
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
NIR Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo
NIR (Near Infrared Spectral Tomography)Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo.
Status: Enrolling
Updated: 9/28/2015
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma
Status: Enrolling
Updated:  9/28/2015
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma
Status: Enrolling
Updated: 9/28/2015
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma
Status: Enrolling
Updated:  9/28/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma
Status: Enrolling
Updated: 9/28/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma
Status: Enrolling
Updated:  9/28/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma
Status: Enrolling
Updated: 9/28/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated:  9/28/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated: 9/28/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated:  9/28/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated: 9/28/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated:  9/28/2015
University of Colorado Cancer Center
mi
from
Denver, CO
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated: 9/28/2015
University of Colorado Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated:  9/28/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated: 9/28/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated:  9/28/2015
MBCCOP - LSU Medical Center
mi
from
New Orleans, LA
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated: 9/28/2015
MBCCOP - LSU Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated:  9/28/2015
Veterans Affairs Medical Center - Ann Arbor
mi
from
Ann Arbor, MI
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated: 9/28/2015
Veterans Affairs Medical Center - Ann Arbor
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated:  9/28/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated: 9/28/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated:  9/28/2015
Veterans Affairs Medical Center - Detroit
mi
from
Detroit, MI
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated: 9/28/2015
Veterans Affairs Medical Center - Detroit
mi
from
Detroit, MI
Click here to add this to my saved trials
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated:  9/28/2015
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated: 9/28/2015
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated:  9/28/2015
Henry Ford Hospital
mi
from
Detroit, MI
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated: 9/28/2015
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated:  9/28/2015
Veterans Affairs Medical Center - Kansas City
mi
from
Kansas City, MO
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II
Status: Enrolling
Updated: 9/28/2015
Veterans Affairs Medical Center - Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials